Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

[1]  C. Borg,et al.  A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. , 2011, Journal of Molecular Diagnostics.

[2]  M. Preusser,et al.  IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. , 2011, Clinical neuropathology.

[3]  J. Hainfellner,et al.  Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens , 2011, Journal of neuropathology and experimental neurology.

[4]  U. Banerji,et al.  Revisiting the role of molecular targeted therapies in patients with brain metastases , 2011, Journal of Neuro-Oncology.

[5]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[6]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[7]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[8]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Herlyn,et al.  Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease , 2011, Clinical Cancer Research.

[11]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[12]  Frank Winkler,et al.  Therapy and prophylaxis of brain metastases , 2010, Expert review of anticancer therapy.

[13]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[14]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[15]  G. Reifenberger,et al.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system , 2009, Acta Neuropathologica.

[16]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[17]  H. Heinzl,et al.  The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry , 2009, Journal of Neuro-Oncology.

[18]  J. Hansson,et al.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site , 2008, Molecular oncology.

[19]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[20]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[21]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[22]  F. Sommerer,et al.  Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.

[23]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[24]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[25]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[26]  M. Ladanyi,et al.  Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. , 2011, The Journal of molecular diagnostics : JMD.